TardiMed Sciences is a life sciences investment and company creation firm. Our team of seasoned biopharmaceutical entrepreneurs have founded, built and exited companies across the spectrum of development stage and commercial stage entities, with a particular focus on de-risked clinical stage assets that have a differentiated profile targeting substantial markets, with the potential to make a major impact on the lives of patients globally.

Castle Creek Pharma is a high growth biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions. The company has a robust and diversified pipeline of late-stage products that have the potential to transform lives.

Marathon Pharmaceuticals was a biopharmaceutical company that developed new treatments for rare diseases with a focus on providing medicine to patients who had no treatment options. The company developed a pipeline of treatments for rare neurologic and movement disorders. Marathon was sold to PTC Therapeutics in 2017.

Norphan Pharmaceuticals was a specialty pharmaceutical company focused on the development of drugs for orphan neurology conditions. Norphan was sold to Marathon Pharmaceuticals in 2013.